Artios Pharma
PrivateLast Round
Series D
Nov 17, 2025
Total Funding Raised
$385.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Artios Pharma operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series D round in November 2025.
Artios Pharma is a biotechnology company developing a pipeline of cancer treatments that target the DNA Damage Response (DDR) process.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Artios Pharma Comparables
Compare Artios Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Repare Therapeutics | 82% | |
| FoRx Therapeutics | 79% | |
| Breakpoint Therapeutics | 79% |
For institutional investors. Book with your work email.
Artios Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Nov 17, 2025 | ||||
| Series C | Jul 27, 2021 | ||||
| Series B | Aug 10, 2018 | ||||
| Series A | Sep 21, 2016 |
For institutional investors. Book with your work email.
Artios Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series C |
| Janus Henderson Group | Series D |
| RA Capital Management | Series D |
| TCG Crossover | Series C |
| Omega Funds | Series D, Series C |
| EQT Life Sciences | Series D, Series C, Series B |
| SV Health Investors | Series B, Series C, Series A, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 16, 2026
Roy W. Ware joins to lead CMSC operations for therapeutics pipeline.
- Jan 7, 2026
Will present at the 44th Annual J.P. Morgan Healthcare Conference.
For institutional investors. Book with your work email.
Artios Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Artios Pharma's valuation, stock price, and market status.
Is Artios Pharma a public or private company?
Artios Pharma is a private company.
What is the current stock price of Artios Pharma?
Artios Pharma is a private company, so its shares have no public market price. Caplight tracks Artios Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Artios Pharma worth (valuation)?
Valuation information for Artios Pharma is not publicly available.
Can I buy Artios Pharma stock?
Artios Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Artios Pharma's last funding round?
Artios Pharma's most recent funding round was Series D on November 17, 2025.
Who are the main investors in Artios Pharma?
Key investors in Artios Pharma include RA Capital Management, TCG Crossover, Omega Funds, EQT Life Sciences, SV Health Investors.
Will Artios Pharma IPO soon?
No public IPO plans have been announced for Artios Pharma.
How can I track Artios Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Artios Pharma's shares on secondary markets.